GILEAD SCIENCES, INC. (GILD) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 2.41B USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 23.83B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 49.36B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $2.41B | $23.83B | (m) | (m) | $49.36B | (m) |
| 2026-03-31 | (m) | (m) | $1.31B | $20.86B | (m) | (m) | $56.28B | (m) |
| 2025-12-31 | (m) | (m) | $2.81B | $22.13B | (m) | (m) | $59.02B | (m) |
| 2025-09-30 | (m) | (m) | $2.81B | $22.14B | (m) | (m) | $58.53B | (m) |
| 2025-06-30 | (m) | (m) | $2.81B | $22.14B | (m) | (m) | $55.72B | (m) |
| 2025-03-31 | (m) | (m) | $2.81B | $22.15B | (m) | (m) | $56.43B | (m) |
| 2024-12-31 | (m) | (m) | $1.81B | $24.90B | (m) | (m) | $58.99B | (m) |
| 2024-09-30 | (m) | (m) | $1.81B | $21.44B | (m) | (m) | $54.52B | (m) |
| 2024-06-30 | (m) | (m) | $1.81B | $21.54B | (m) | (m) | $53.58B | (m) |
| 2024-03-31 | (m) | (m) | $3.67B | $21.53B | (m) | (m) | $56.29B | (m) |
| 2023-12-31 | (m) | (m) | $1.80B | $23.19B | (m) | (m) | $62.13B | (m) |
| 2023-09-30 | (m) | (m) | $1.79B | $23.19B | (m) | (m) | $62.37B | (m) |
| 2023-06-30 | (m) | (m) | $4.04B | $21.21B | (m) | (m) | $62.34B | (m) |
| 2023-03-31 | (m) | (m) | $2.28B | $22.96B | (m) | (m) | $61.88B | (m) |
| 2022-12-31 | (m) | (m) | $2.27B | $22.96B | (m) | $6.38B | $63.17B | (m) |
| 2022-09-30 | (m) | (m) | $2.27B | $22.95B | (m) | (m) | $62.56B | (m) |
| 2022-06-30 | (m) | (m) | $1.02B | $25.20B | (m) | (m) | $62.87B | (m) |
| 2022-03-31 | (m) | (m) | $1.02B | $25.18B | (m) | (m) | $63.08B | (m) |
| 2021-12-31 | (m) | (m) | $1.52B | $25.18B | (m) | $6.52B | $67.95B | (m) |
| 2021-09-30 | (m) | (m) | $2.51B | $25.18B | (m) | (m) | $67.10B | (m) |
| 2021-06-30 | (m) | (m) | $2.26B | $27.91B | (m) | (m) | $67.98B | (m) |
| 2021-03-31 | (m) | (m) | $2.26B | $27.91B | (m) | (m) | $67.49B | (m) |
| 2020-12-31 | (m) | (m) | $2.76B | $28.64B | (m) | $7.41B | $68.41B | (m) |
| 2020-09-30 | (m) | (m) | $1.50B | $27.79B | (m) | (m) | $60.88B | (m) |
| 2020-06-30 | (m) | (m) | $3.00B | $21.10B | (m) | (m) | $55.93B | (m) |
| 2020-03-31 | (m) | (m) | $2.00B | $22.10B | (m) | (m) | $59.74B | (m) |
| 2019-12-31 | (m) | (m) | $2.50B | $22.09B | (m) | $24.35B | $61.63B | (m) |
| 2019-09-30 | (m) | (m) | $2.50B | $22.09B | (m) | (m) | $59.15B | (m) |
| 2019-06-30 | (m) | (m) | $2.00B | $24.08B | (m) | $27.18B | $63.21B | (m) |
| 2019-03-31 | (m) | (m) | $2.50B | $24.08B | (m) | $27.90B | $62.84B | (m) |
| 2018-12-31 | (m) | (m) | $2.75B | $24.57B | (m) | $30.09B | $63.67B | (m) |
| 2018-09-30 | (m) | (m) | $2.75B | $24.57B | (m) | $28.47B | $64.31B | (m) |
| 2018-06-30 | (m) | (m) | $3.00B | $26.06B | (m) | $25.92B | $65.36B | (m) |
| 2018-03-31 | (m) | (m) | $2.50B | $26.56B | (m) | $24.00B | $65.38B | (m) |
| 2017-12-31 | (m) | (m) | $2.75B | $30.80B | (m) | $25.51B | $70.28B | (m) |
| 2017-09-30 | (m) | (m) | $1.75B | $27.52B | (m) | $28.39B | $64.66B | (m) |
| 2017-06-30 | (m) | (m) | $0.00 | $26.30B | (m) | $21.10B | $60.26B | (m) |
| 2017-03-31 | (m) | (m) | $0.00 | $26.32B | (m) | $14.12B | $57.70B | (m) |
| 2016-12-31 | (m) | (m) | $0.00 | $26.35B | (m) | $11.89B | $56.98B | (m) |
| 2016-09-30 | (m) | (m) | $700.00M | $26.37B | (m) | $12.27B | $56.61B | (m) |
| 2016-06-30 | (m) | (m) | $700.00M | $21.43B | (m) | $8.75B | $49.98B | (m) |
| 2016-03-31 | (m) | (m) | $953.00M | $21.08B | (m) | $8.32B | $47.77B | (m) |
| 2015-12-31 | (m) | (m) | $983.00M | $21.20B | (m) | $14.61B | $51.84B | (m) |
| 2015-09-30 | (m) | (m) | $331.00M | $21.89B | (m) | $15.71B | $50.64B | (m) |
| 2015-06-30 | (m) | (m) | $352.00M | $11.92B | (m) | $8.61B | $39.17B | (m) |
| 2015-03-31 | (m) | (m) | $442.00M | $11.92B | (m) | $11.29B | $38.32B | (m) |
| 2014-12-31 | (m) | (m) | $483.00M | $11.92B | (m) | $10.13B | $34.66B | (m) |
| 2014-09-30 | (m) | (m) | $1.48B | $7.93B | (m) | $6.32B | $28.84B | (m) |
| 2014-06-30 | (m) | (m) | $1.57B | $7.93B | (m) | $8.80B | $31.21B | (m) |
| 2014-03-31 | (m) | (m) | $1.87B | $7.93B | (m) | $6.47B | $28.08B | (m) |
| 2013-12-31 | (m) | (m) | $2.70B | $3.94B | (m) | $2.13B | $22.50B | (m) |
| 2013-09-30 | (m) | (m) | $1.46B | $5.86B | (m) | $2.09B | $22.47B | (m) |
| 2013-06-30 | (m) | (m) | $-1.49B | $5.85B | (m) | $2.29B | $22.62B | (m) |
| 2013-03-31 | (m) | (m) | $-942.76M | $7.05B | (m) | $1.94B | $22.21B | (m) |
| 2012-12-31 | (m) | (m) | $-1.17B | $7.05B | (m) | $1.86B | $21.24B | (m) |
| 2012-09-30 | (m) | (m) | $1.73B | $7.04B | (m) | $1.70B | $20.96B | (m) |
| 2012-06-30 | (m) | (m) | $1.97B | $7.13B | (m) | $1.71B | $20.50B | (m) |
| 2012-03-31 | (m) | (m) | $1.35B | $8.08B | (m) | $1.45B | $19.95B | (m) |
| 2011-12-31 | (m) | (m) | $0.00 | $7.61B | (m) | $9.90B | $17.30B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |